After barely beating its 2023 vaccine-sales outlook, which Moderna adjusted to the lower end of its previous forecast last quarter, the Cambridge company is gearing up for a future beyond Covid-19 vaccines.
Moderna reported $6.1 billion in vaccine sales for the 2023 fiscal year during its fourth-quarter earnings on Thursday. That number excludes roughly $600 million in deferred revenue related to Gavi, the Vaccine Alliance, which supplies Covid-19 vaccines to lower-income countries.
WATCH ANYTIME FOR FREE
 |
Stream NBC10 Boston news for free, 24/7, wherever you are. |
More on this story from Boston Business Journal
Get updates on what's happening in Boston to your inbox. Sign up for our News Headlines newsletter.
Copyright Boston Business Journal
